全文获取类型
收费全文 | 832篇 |
免费 | 102篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 26篇 |
妇产科学 | 9篇 |
基础医学 | 135篇 |
口腔科学 | 54篇 |
临床医学 | 60篇 |
内科学 | 129篇 |
皮肤病学 | 48篇 |
神经病学 | 80篇 |
特种医学 | 49篇 |
外科学 | 107篇 |
综合类 | 12篇 |
一般理论 | 1篇 |
预防医学 | 54篇 |
眼科学 | 5篇 |
药学 | 54篇 |
肿瘤学 | 119篇 |
出版年
2021年 | 16篇 |
2020年 | 15篇 |
2019年 | 12篇 |
2018年 | 14篇 |
2017年 | 11篇 |
2016年 | 14篇 |
2015年 | 16篇 |
2014年 | 17篇 |
2013年 | 34篇 |
2012年 | 29篇 |
2011年 | 38篇 |
2010年 | 31篇 |
2009年 | 21篇 |
2008年 | 41篇 |
2007年 | 40篇 |
2006年 | 43篇 |
2005年 | 47篇 |
2004年 | 37篇 |
2003年 | 26篇 |
2002年 | 19篇 |
2001年 | 18篇 |
2000年 | 33篇 |
1999年 | 21篇 |
1998年 | 18篇 |
1997年 | 11篇 |
1996年 | 12篇 |
1995年 | 7篇 |
1994年 | 12篇 |
1993年 | 9篇 |
1992年 | 27篇 |
1991年 | 22篇 |
1990年 | 21篇 |
1989年 | 17篇 |
1988年 | 16篇 |
1987年 | 15篇 |
1986年 | 9篇 |
1985年 | 7篇 |
1984年 | 8篇 |
1983年 | 10篇 |
1981年 | 6篇 |
1980年 | 6篇 |
1979年 | 8篇 |
1977年 | 6篇 |
1975年 | 7篇 |
1974年 | 5篇 |
1972年 | 6篇 |
1971年 | 7篇 |
1969年 | 7篇 |
1967年 | 6篇 |
1966年 | 8篇 |
排序方式: 共有945条查询结果,搜索用时 0 毫秒
81.
David M. Peereboom Jeffrey G. Supko Kathryn A. Carson Tracy Batchelor Surasak Phuphanich Glenn Lesser Tom Mikkelson Joy Fisher Serena Desideri Xiaoying He Stuart A. Grossman 《Journal of neuro-oncology》2010,100(2):261-268
Ixabepilone is an epothilone, a novel class of non-taxane microtubule stabilizing agents. A phase I/II and pharmacokinetic trial of ixabepilone was conducted in patients with recurrent high-grade gliomas. Adult patients received ixabepilone as a 1-h infusion daily for 5 days every 3 weeks. A modified continual reassessment method was used to escalate doses, beginning at 5.0 mg/m2, in patients stratified by use or non-use of enzyme inducing antiepileptic drugs (EIAED). In the phase I study, the maximum tolerated dose (MTD) and pharmacokinetics of ixabepilone were determined for each group. The phase II study used a two-stage design to evaluate response rate. Secondary endpoints were survival and 6-month progression free survival. In the phase I trial, 38 patients (median age 54 years) were enrolled. The MTD was 6.8 mg/m2 for patients not taking EIAEDs and 9.6 mg/m2 for those taking EIAEDs. The dose limiting toxicities in both groups were hematologic. Twenty-three patients (median age 54 years) were enrolled in the first stage of the phase II trial. No objective responses were observed. Median overall survival was 5.8 (95% CI, 5.0–8.6) months and 6-month PFS rate was 4% (95% CI, 0–22%). The overall mean total body clearance for ixabepilone was significantly higher (P = 0.003) in patients receiving EIAEDs (36 ± 11 l/h/m2) than those not (24 ± 9.2 l/h/m2). Patients on EIAEDs had a substantially higher MTD likely due to induction of cytochrome P450. Ixabepilone had no activity in patients with recurrent high-grade gliomas. 相似文献
82.
83.
84.
Background
The decline in caries has slowed and this may be indicative of variation in the susceptibility of differing teeth to caries. This study tests the hypothesis that in children, there are groups of tooth sites that exhibit differences in caries susceptibility. 相似文献85.
86.
S J Deacock A P Schwarer J Bridge J R Batchelor J M Goldman R I Lechler 《Transplantation》1992,53(5):1128-1134
Umbilical cord blood has been used to effect hematological reconstitution and there are sufficient stem cells available in the cord blood obtainable from a single placenta to reconstitute an adult patient. Umbilical cord blood might therefore, have widespread potential use in the field of bone marrow transplantation. We compared alloreactivity of paired samples of adult and cord peripheral blood mononuclear cells, by measuring frequencies of both alloreactive T helper cells and cytotoxic T cell precursors (CTLp), using limiting dilution analysis. In addition we compared the phenotype of adult and neonatal PBMC, using monoclonal antibody staining. Cord PBMC in general showed higher frequencies of alloreactive Th than adult PBMC, with statistically significant differences in 6 out of 10 experiments. There was no statistically significant difference between adult and cord CTLp frequencies. Adult and cord PBMC surface phenotype was similar, except that cord blood contained fewer lymphocyte function-associated-3 (LFA-3) positive (memory) cells. 相似文献
87.
88.
Phase 2 trial of high‐dose rituximab with high‐dose cytarabine mobilization therapy and high‐dose thiotepa,busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non‐Hodgkin lymphoma 下载免费PDF全文
Yi‐Bin Chen MD Tracy Batchelor MD MPH Shuli Li MD Ephraim Hochberg MD Mark Brezina MD Sooae Jones NP Candice Del Rio RN Morgan Curtis MD Karen K. Ballen MD Jeffrey Barnes MD PhD Andrew S. Chi MD PhD Jorg Dietrich MD PhD Jessica Driscoll NP Elizabeth R. Gertsner MD Fred Hochberg MD Ann S. LaCasce MD Steven L. McAfee MD Thomas R. Spitzer MD Lakshmi Nayak MD Philippe Armand MD PhD 《Cancer》2015,121(2):226-233
89.
90.
Gabriela?A?LamarcaEmail author Maria?do?C?Leal Anna?TT?Leao Aubrey?Sheiham Mario?V?Vettore 《Health and quality of life outcomes》2012,10(1):5